Vtv Theraptcs Cl A (VTVT)

$20.90 +0.06 (0.29%)
Market Cap 82.07M
Revenue (ttm) 1.02M
Net Income (ttm) -18.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,809.80%
Debt to Equity Ratio 0.00
Volume 1,800
Avg Vol 4,170
Day's Range N/A - N/A
Shares Out 3.94M
Stochastic %K 48%
Beta 0.67
Analysts Sell
Price Target $35.50

Company Profile

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for t...

Industry: Biotechnology
Sector: Healthcare
Phone: 336 841 0300
Fax: 336 841 0310
Address:
3980 Premier Drive, Suite 310, High Point, United States
km1663
km1663 Oct. 16 at 2:24 PM
$VTVT Were down 11% on 240 share's? Yea right!
1 · Reply
Estockpicker
Estockpicker Oct. 14 at 12:57 PM
$VTVT have They started phase 3 trials? Are they still paying a PR person? Seems they have an issue with giving information .
1 · Reply
Tradingistheway
Tradingistheway Oct. 9 at 7:10 PM
$VTVT no what show off
0 · Reply
Samiam69
Samiam69 Oct. 9 at 4:16 PM
$VTVT come on already we should be at 50 need the news she eats up the gas 🐢🐢🐢
0 · Reply
Social_Idiot
Social_Idiot Oct. 9 at 3:54 PM
$VTVT Captured a few more shares in the mid 20s.
0 · Reply
LongBallBarn
LongBallBarn Oct. 9 at 3:53 PM
$VTVT
0 · Reply
Estockpicker
Estockpicker Oct. 9 at 2:32 PM
$VTVT interesting stock. So many articles about hiring people but zero data
1 · Reply
GDS_investing
GDS_investing Oct. 9 at 12:05 PM
$VTVT NEWS OUT: "vTv Therapeutics Announces New Appointments to its Scientific Advisory Board" https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-new-appointments-its-scientific
0 · Reply
Estockpicker
Estockpicker Oct. 8 at 1:15 PM
$VTVT So they have raised a significant amount of money but what exactly are they doing with It? Research has suggested they do not inform shareholders of exactly what they are doing
1 · Reply
Samiam69
Samiam69 Oct. 7 at 4:13 PM
$VTVT 🐢🐢🐢🐢🐢
0 · Reply
Latest News on VTVT
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 16 days ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 15, 2025, 8:00 AM EDT - 5 weeks ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 4:57 PM EDT - 7 weeks ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 7 weeks ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:15 PM EDT - 2 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 11, 2025, 8:00 AM EDT - 2 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Aug 7, 2025, 8:00 AM EDT - 2 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 11, 2025, 8:00 AM EDT - 4 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025, 9:00 AM EDT - 5 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 5 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025, 12:00 PM EDT - 5 months ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 20, 2025, 5:35 PM EDT - 7 months ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 1:59 PM EDT - 7 months ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Mar 17, 2025, 8:30 AM EDT - 7 months ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 9, 2024, 7:33 AM EST - 11 months ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Dec 2, 2024, 4:05 PM EST - 11 months ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

Jun 24, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 28, 2024, 8:00 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

May 9, 2024, 4:51 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 19, 2024, 8:30 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 13, 2024, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 4, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 28, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Feb 22, 2024, 4:00 PM EST - 1 year ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 16, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

Jun 15, 2023, 7:33 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 24, 2023, 9:00 AM EDT - 2 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 11, 2023, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Apr 20, 2023, 8:00 AM EDT - 2 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 5:56 PM EST - 2 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Mar 6, 2023, 8:02 AM EST - 2 years ago

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 27, 2023, 8:02 AM EST - 2 years ago

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

Feb 1, 2023, 5:00 PM EST - 2 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Jan 9, 2023, 8:00 AM EST - 3 years ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Dec 13, 2022, 8:15 AM EST - 3 years ago

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Nov 10, 2022, 5:25 PM EST - 3 years ago

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

Aug 15, 2022, 6:43 PM EDT - 3 years ago

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

km1663
km1663 Oct. 16 at 2:24 PM
$VTVT Were down 11% on 240 share's? Yea right!
1 · Reply
Estockpicker
Estockpicker Oct. 14 at 12:57 PM
$VTVT have They started phase 3 trials? Are they still paying a PR person? Seems they have an issue with giving information .
1 · Reply
Tradingistheway
Tradingistheway Oct. 9 at 7:10 PM
$VTVT no what show off
0 · Reply
Samiam69
Samiam69 Oct. 9 at 4:16 PM
$VTVT come on already we should be at 50 need the news she eats up the gas 🐢🐢🐢
0 · Reply
Social_Idiot
Social_Idiot Oct. 9 at 3:54 PM
$VTVT Captured a few more shares in the mid 20s.
0 · Reply
LongBallBarn
LongBallBarn Oct. 9 at 3:53 PM
$VTVT
0 · Reply
Estockpicker
Estockpicker Oct. 9 at 2:32 PM
$VTVT interesting stock. So many articles about hiring people but zero data
1 · Reply
GDS_investing
GDS_investing Oct. 9 at 12:05 PM
$VTVT NEWS OUT: "vTv Therapeutics Announces New Appointments to its Scientific Advisory Board" https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-new-appointments-its-scientific
0 · Reply
Estockpicker
Estockpicker Oct. 8 at 1:15 PM
$VTVT So they have raised a significant amount of money but what exactly are they doing with It? Research has suggested they do not inform shareholders of exactly what they are doing
1 · Reply
Samiam69
Samiam69 Oct. 7 at 4:13 PM
$VTVT 🐢🐢🐢🐢🐢
0 · Reply
Samiam69
Samiam69 Oct. 7 at 2:11 PM
$VTVT Time to release the hounds 🐢🐢🐢
0 · Reply
JimJames
JimJames Oct. 6 at 8:16 PM
$VTVT better be scheming something good with these warrants
0 · Reply
Estockpicker
Estockpicker Oct. 6 at 3:17 PM
$VTVT is there huge dilution in this stock or are they shelf shares
2 · Reply
GDS_investing
GDS_investing Oct. 6 at 2:07 PM
$VTVT pm gift tnx... long next targets 31 then 56
1 · Reply
Samiam69
Samiam69 Oct. 3 at 11:26 PM
$VTVT there goes the 650k float 🐢🐢🐢
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 3 at 8:52 PM
$VTVT
0 · Reply
Newtrader_covid19
Newtrader_covid19 Oct. 3 at 7:10 PM
$VTVT $VTVT finally break even. Holding this long before RS and 2026 phase 3 trial result will push this 5 fold. It’s already been above 3 years.I am positive it will return me Enough to pay off my mortgage 💪🏻
0 · Reply
Social_Idiot
Social_Idiot Oct. 2 at 2:13 PM
$VTVT I have to say that I find this stock attractive but between the low float and low volume, the volatility makes it hard to trust.
1 · Reply
Estockpicker
Estockpicker Sep. 30 at 3:29 PM
$VTVT interesting stock. what is the catalyst that will drive this stock higher
1 · Reply
Mik21212
Mik21212 Sep. 26 at 6:44 PM
$VTVT in, glta
0 · Reply
dcajic2
dcajic2 Sep. 26 at 2:55 PM
$VTVT Reality land. There are well over 2 million shares outstanding plus if the 80 million investment goes through many more shares will be added
0 · Reply
GDS_investing
GDS_investing Sep. 26 at 2:20 PM
$VTVT looking great and strong golden cross is in 50ma vs 200ma = huge long need more volume float only 640k
1 · Reply